Pathophysiology and endoscopic/balloon treatment of esophageal motility disorders.
Diagnostic and therapeutic dilemmas associated with esophageal dysmotility syndromes continue to confront physicians managing these patient populations. Although modern manometric systems have allowed us to better define normal parameters of esophageal motility, with the exception of primary achalasia, the clinical relevance of many aberrant motor patterns remains unclear. The novel use of botulinum toxin in idiopathic achalasia stems from increased understanding of the pathogenesis of the disease. Similarly, as our knowledge of the pathophysiology of other esophageal motor disorders grows, in conjunction with improved diagnostic capabilities, more effective management strategies may be used in the future.
Koshy
S S
SS
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA.
Nostrant
T T
TT
D001905:Botulinum Toxins / Q000627:therapeutic use; D002404:Catheterization; D004931:Esophageal Achalasia / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D015155:Esophageal Spasm, Diffuse / Q000628:therapy; D004945:Esophagoscopy; D004947:Esophagus / Q000473:pathology / Q000601:surgery; D006801:Humans; D010535:Laparoscopy; D008365:Manometry
D001905:Botulinum Toxins